Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014:2014:417091.
doi: 10.1155/2014/417091. Epub 2014 May 25.

Radiopharmaceutical stem cell tracking for neurological diseases

Affiliations
Review

Radiopharmaceutical stem cell tracking for neurological diseases

Paulo Henrique Rosado-de-Castro et al. Biomed Res Int. 2014.

Abstract

Although neurological ailments continue to be some of the main causes of disease burden in the world, current therapies such as pharmacological agents have limited potential in the restoration of neural functions. Cell therapies, firstly applied to treat different hematological diseases, are now being investigated in preclinical and clinical studies for neurological illnesses. However, the potential applications and mechanisms for such treatments are still poorly comprehended and are the focus of permanent research. In this setting, noninvasive in vivo imaging allows better understanding of several aspects of stem cell therapies. Amongst the various methods available, radioisotope cell labeling has become one of the most promising since it permits tracking of cells after injection by different routes to investigate their biodistribution. A significant increase in the number of studies utilizing this method has occurred in the last years. Here, we review the different radiopharmaceuticals, imaging techniques, and findings of the preclinical and clinical reports published up to now. Moreover, we discuss the limitations and future applications of radioisotope cell labeling in the field of cell transplantation for neurological diseases.

PubMed Disclaimer

References

    1. Catalá-López F, Gènova-Maleras R, Vieta E, Tabarés-Seisdedos R. The increasing burden of mental and neurological disorders. European Neuropsychopharmacology. 2013;23(11):1337–1339. - PubMed
    1. Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet. 2013;380(9859):2197–2223. - PubMed
    1. Burt RK, Loh Y, Pearce W, et al. Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. JAMA. 2008;299(8):925–936. - PubMed
    1. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS ONE. 2012;7(10)e47559 - PMC - PubMed
    1. Palestro CJ, Love C, Bhargava KK. Labeled leukocyte imaging: current status and future directions. Quarterly Journal of Nuclear Medicine and Molecular Imaging. 2009;53(1):105–123. - PubMed

Publication types

Substances

LinkOut - more resources